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Abstract 
Objective Alterations in phenotype and function of endothelial progenitor cells (EPCs) have been associated with poor vascular outcomes and impaired vascular repair in various conditions. Our hypothesis was that patients with polymyositis (PM) and dermatomyositis (DM) have dysregulation of EPCs driven by type I interferons (IFN) and interleukin (IL)-18 similar to other autoimmune diseases.
Methods Quantification of circulating EPCs was performed by flow cytometry in patients with PM/DM and matched healthy controls. The ability of EPCs to differentiate into mature endothelial cells (ECs) was investigated by light and fluorescence microscopy quantification in the presence or absence of PM/DM or control serum, neutralizing antibodies to type I IFN receptor or IL-18. Serum type I IFN activity was quantified by induction of type I-IFN inducible genes (ISG) in HeLa cells. Circulating IL-18 concentrations were assessed by ELISA.
Results Circulating EPCs were significantly lower in PM/DM patients compared to controls. PM/DM EPCs displayed a decreased capacity to differentiate into mature ECs and PM/DM serum significantly inhibited differentiation of control EPCs. This effect was reversed in the majority of samples with neutralizing antibodies to IL-18 or to type I IFN receptor or by a combination of these antibodies. Patients with associated impairments in EPC function had higher type I IFN serum activity.
 Conclusions PM/DM is associated with dysregulation of EPC phenotype and function that may be attributed, at least in part, to aberrant IL-18 and type I IFN pathways. The implication of these vasculopathic findings to disease prognosis and complications remains to be determined.






Polymyositis (PM) and dermatomyositis (DM) are characterized by proximal muscle weakness and inflammation of muscles and other organs, such as skin and lungs, and commonly associated to the presence of autoantibodies [].
The molecular mechanisms driving the inflammation in patients with PM/DM are not fully understood. Some of the organ manifestations, such as skin rash and low muscle endurance could possibly be explained by a loss of microvessels. A low number of capillaries in muscle biopsies is a hallmark of DM, and was reported as an early finding also in PM []. Thus loss of microvessels may contribute to the pathogenesis of PM/DM and promote organ ischemia and myofiber atrophy. In patients with systemic lupus erythematosus (SLE), a disease associated with cardiovascular complications and vascular rarefaction in various organs, a dysfunction in the phenotype and function of endothelial progenitor cells (EPCs), cells involved in the regeneration of the endothelial lining of blood vessels, has been observed and proposed to play a role in premature vascular damage, poor pregnancy outcomes and end-stage renal disease ADDIN EN.CITE []. In lupus, EPC dysfunction is driven by the type I interferon (IFN) pathway and has also been associated to activation of the inflammasome machinery, leading to vasculopathic changes promoted by IL-18  ADDIN EN.CITE []. A type-I IFN signature has been demonstrated in patients with idiopathic inflammatory myopathies, particularly in DM and in patients with PM and autoantibodies to RNA binding proteins  ADDIN EN.CITE [, ]. IL-18 has been noted to be upregulated in endomysial and perimysial macrophages  ADDIN EN.CITE []. Therefore, we hypothesized that loss of microvessels in patients with PM/DM might be mediated by EPC dysregulation driven by type I IFNs and IL-18. The aim of the study was to assess if patients with PM/DM have EPC perturbations similar to other autoimmune diseases.

Patients and methods
To investigate serum effects on EPC differentiation, 36 serum samples (PM=24, DM=12) from the well-characterized myositis cohort at Karolinska University Hospital, Stockholm, Sweden were included (cohort 1) []. For quantification and differentiation properties of EPCs, fresh PBMCs from 25 patients with PM (n=17) or DM (n=8) were obtained between 2010-2012 at the outpatient Rheumatology Clinic, University of Michigan, Ann Arbor, USA (cohort 2). Exclusion criteria were IBM, current or recent infections (within 1 week), pregnancy or cancer. The patients in both cohorts fulfilled the criteria of definite or probable DM and PM []. Demographic data and clinical characteristics are shown in table 1. Matched healthy controls were recruited by advertisement at the University of Michigan. The design of this work was approved by the Regional Ethical Review Board in Stockholm and in Ann Arbor and all subject’s written consent was obtained according to the Declaration of Helsinki. (Ethical permit Karolinska hospital, Stockholm, Sweden: D-nr 2005/792-31/4 and 2011/1374-32 and University of Michigan, USA study ID: HUM00044257, HUM 00066116).

Clinical and laboratory data
Disease activity at the time of serum sampling was assessed according to the International Myositis Assessment and Clinical Studies (IMACS) Group  ADDIN EN.CITE [], based on prospectively collected data (cohort 1). Information on medications and laboratory data was retrieved from patient records in both cohorts (Table 1). Serum levels of muscle enzymes were analyzed as routine tests at the local Departments of Clinical Chemistry, and ANA status was analyzed by immunofluorescence (IFL) as a routine test at the Department of Clinical Immunology Karolinska University Hospital, Sweden (cohort 1) and the Clinical Labs at the University of Michigan (cohort 2).

Autoantibody assays
Cohort 1 samples were screened for autoantibodies using immunoprecipitation as previously described [] and were quantified using a validated immunoassay system (Euroimmun, Lübeck, Germany). Serum samples in cohort 2 were screened for similar autoantibodies using a BioPlex 2200 assay, at the University of Michigan Clinical Pathology Lab.
Patients were defined as positive for an autoantibody if status was positive in at least one of the two used methods (cohort 1). 

Characterization of bone marrow derived EPCs
Circulating EPCs were quantified in cohort 2 and matched controls as previously described  ADDIN EN.CITE [].  See supplementary data for more detailed methods, available at Rheumatology online.
In vitro differentiation into mature ECs
PBMC differentiation into EC-like cells is an accepted method to assess the functionality of EPCs  ADDIN EN.CITE [, ]. This was performed as previously described  ADDIN EN.CITE [, ] with a few modifications (see supplementary methods available at Rheumatology online for details).
To assess the effect of PM/DM serum on EPC differentiation into mature ECs, we proceeded to isolate healthy control EPC-containing PBMCs and cultured them in proangiogenic conditions as above, in the presence or absence of 30 % healthy control or PM/DM serum from cohort 1, for the first three days of culture. Blocking experiments are described in supplementary methods available at Rheumatology online. 

Serum IL-18 quantification 
Serum IL-18 was quantified in cohorts 1 and 2 with human IL-18 ELISA kit (Ebioscience, San Diego, CA) according to manufacturer’s instructions. 

Type I IFN serum activity
PM/DM serum samples (cohort 1) or control samples were assayed for their capacity to induce IFN-inducible genes (ISGs) on HeLa cells using a bioassay previously described  ADDIN EN.CITE [] (see supplementary methods available at Rheumatology online).

Statistical analyses
Analyses were done using GraphPad Prism 6 Software. The significance of differences between non-normally distributed groups was calculated by Mann-Whitney U test.  Correlation analyses were performed using linear regression analysis. Comparison of improvement with IL-18 or IFNR1 blockade was performed using paired, 2-sided student’s t-test. Difference between the means in the EPC quantification and monolayer assay was analyzed using an unpaired student’s t-test. P-values <0.05 were considered statistically significant.

Results 
PM/DM is associated with decreases in numbers and function of circulating EPCs 
A significantly lower number of circulating EPCs was detected in patients with PM and DM compared to controls (figure 1A). The significance persisted when comparing PM alone vs controls (p=0.0116), but not when comparing DM alone vs controls. Low EPC numbers were not secondary to leukopenia as there was no correlation between EPC numbers/ml blood and PBMCs/ml of blood (p-value= 0.7360, R2= 0.005038).Furthermore, both PM and DM EPCs displayed a significantly lower capacity to differentiate into a monolayer of mature ECs, when compared to healthy controls (figure 1B). This significance persisted when DM was compared to controls (p=0.0350). Overall, these results indicate that EPCs isolated from patients with PM and DM are decreased in numbers and function. However there was no correlation between EPC numbers and monolayer formation. 

PM/DM sera impair EPC differentiation
Next, we investigated if sera from patients with PM or DM inhibited EPCs differentiation into mature ECs. Based on a cut-off of 90% of healthy controls, patients were categorized into two groups: a) serum that inhibited EPC differentiation or b) unchanged EPC differentiation. Significant inhibition of EPC differentiation into ECs compared to controls was observed in 25 patients (70 %), whereas no significant inhibition was detected in 11 patients (30%). Given that in SLE, disruptions in EPC differentiation had been associated to the type I IFN signature and to IL-18, we tested if the disruptions in EPC function in PM/DM could be abrogated by blocking IL-18 and/or type-I IFN receptor. Of the 25 patients in which sera displayed an inhibitory effect on EPC differentiation compared to healthy control serum, 60% (15 patients) and 52 % (13 patients) of samples showed improvement of abnormal EPC phenotype with IL-18 or type I IFN receptor neutralization, respectively, and this was significant using paired analysis (Figure 1C, supplementary figure 1). In 4 of these patients (16%), the effect was IL-18 specific; in 2 patients (8%) it was type-I IFN receptor specific, while in 11 patients (44%), the effect was reversed by both strategies. In 8 patients (32%), the abnormal phenotype could not be abrogated by any of the blocking strategies. Patients with PM/DM had significantly higher serum levels of IL-18 73(5-285) pg/ml versus undetectable in controls (p=<0.0001). However, IFN score or IL-18 concentration did not correlate with in vitro improvement with respective cytokine blockade (supplementary figure 2). However, sera displaying EPC inhibitory activity had significantly higher type I IFN serum activity (Figure 1D) than sera that did not display inhibition of EPC function. Overall, these results indicate that type I IFNs and IL-18 play a role in inducing abnormal function of EPCs in PM/DM in a majority of patients, and that the type I IFN serum activity is associated to disruptions in EPC function.

Correlation between clinical parameters and EPC differentiation in PM/DM




Microcirculatory disturbances have been proposed to play a role in the pathogenesis of PM and DM, as phenotypically altered small vessels could affect the local muscle circulation promoting tissue hypoxia, metabolic alterations and muscle weakness. However, the mechanisms leading to vascular rarefaction in these disorders remain to be characterized. Accumulating data indicate a role for type I IFNs in PM and DM with regards to myofiber injury and disease activity  ADDIN EN.CITE []. An elevated type I IFN signature has been reported in a significant proportion of patients with PM/DM. 

Our group previously reported that type I IFNs may play a prominent role in inducing lupus vasculopathy. A key mechanism by which these cytokines are deleterious to blood vessels is by inducing impairments in the phenotype and function of EPCs, thereby hampering vascular repair. Indeed, type I IFNs activate important antiangiogenic pathways in endothelial precursors and in ECs, including repression of vascular endothelial growth-factor, upregulation of the IL-1 receptor antagonist and activation of the inflammasome machinery, particularly IL-18 activation  ADDIN EN.CITE []. We therefore hypothesized that type I IFNs could play prominent roles in altering the vasculature in PM and DM, thereby promoting capillary rarefaction or larger vessel vasculopathy. Indeed, we found that a significant proportion of patients with PM/DM displayed decreased circulating EPCs, as well as decreased capacity of blood-derived endothelial precursors to differentiate into EC-like cells in vitro when exposed to proangiogenic stimulation. Importantly, this impairment appears to be mediated, at least in part, by the type I IFN/IL-18 axis, as neutralization of this pathway led to significant restoration of differentiation into ECs in control EPCs exposed to PM/DM sera. These results are very similar to what we previously observed in SLE patients  ADDIN EN.CITE []. Whether IFNα or IFNβ is more important in PM/DM still needs to be defined ADDIN EN.CITE [].
These observed abnormalities in EPCs appear to apply to both DM and PM, where decreases in EPC numbers appear to be more prominent in PM, while DM EPCs were more dysfunctional. Interestingly, while the IFN signature has been associated primarily to DM and to autoantibody-positive PM, we did not find a significant association between autoantibodies or circulating IL-18 and impairments in vascular repair. In contrast, the type-I IFN signature significantly correlated with EPC impairments, further supporting the hypothesis that these cytokines are key in inducing vascular dysfunction in autoimmunity. The effects of IL-18/IFN on EPC function may be at the paracrine level, thus explaining why blockade in culture is effective but correlation with serum IL-18/IFN score is not seen. Larger numbers of patients with PM/DM should be studied in the future to be able to distinguish subsets of patients at risk for vasculopathy due to defects in vascular repair. Further assessment of other potential pathways downstream of type I IFNs, beyond IL-18, that may be relevant as therapeutic targets in PM/DM is also warranted. Indeed, the normal function of EPCs could not be restored when approximately a third of the serum samples were neutralized with anti-IFN and/or anti-IL-18 therapy, implicating that in a subset of individuals other pathways may play prominent roles in disrupting vascular repair. Alternatively, there may be patients where higher concentrations of neutralizing antibodies are needed to recover a normal vascular phenotype.

As in SLE, PM and DM are characterized by phenotypic and functional EPC abnormalities, which are likely triggered by the type I IFN/IL-18 axis. Longitudinal assessments are needed to evaluate whether progression of vascular damage, muscle and organ-specific outcomes in PM and DM are associated to EPC dysregulation in association with the type I IFN pathway. As anti-type I IFN therapies are currently being explored in PM and DM, it will be important to incorporate surrogates of vascular repair and vasculopathy as part of the evaluation of therapeutic efficacy.  

Rheumatology key messages
	PM/DM is associated with dysregulation of EPC phenotype and function 
	EPC dysregulation in PM/DM may be attributed, in part, to IL-18 and type I IFN pathways. 
	Further research into the role of endothelial function in PM/DM may provide therapeutic insights. 
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Figure 1. Endothelial progenitor cell numbers and capacity to differentiate into mature ECs is impaired in PM/DM. A. Results represent mean+SEM circulating EPC numbers/ml of blood of 17 controls and 25 PM/DM patients assessed as described in methods. B. Results represent the mean % of control or myositis samples that formed an EC monolayer after 2 weeks in culture. C. Graph depicts percent inhibition of EPC differentiation of control PBMCs when exposed to myositis serum as compared to control serum in the presence or absence of neutralizing antibodies to IFNR1 or IL-18. The y-axis shows the effect of myositis serum +/-antibodies on EPC differentiation as compared to the effects of healthy control serum. D. Results display the composite interferon score as divided by whether the serum was able to interrupt EPC differentiation in vitro.  *=p<0.05, ***=p<0.001

Supplementary figure 1. Myositis sera inhibits EPC differentiation in vitro. Representative fluorescent photomicrograph examining staining of ac-LDL (red) and UEA-1 (green) in EC cultures at day 14 with and without type I IFN blockade or IL-18 neutralization. The overlap yellow staining represents cells that are double positive and most likely a mature EC.

Supplementary figure 2. IFN score or IL-18 levels do not correlate with in vitro improvement with respective cytokine blockade. A. Line represents linear regression of serum IL-18 versus percent improvement of EPC differentiation with neutralizing antibodies to IL-18. B. IFN score versus % improvement with antibodies to type I IFN receptor blockade in all patients or only in those patients whose serum caused inhibition of EPC differentiation.  No difference between the groups was noted.  






































Table 1. Patient characteristics at baseline
Characteristics*	Cohort 1n=36	Cohort 2n=25	
Diagnosis, n (%)			
    PM°	24 (67)	17 (68)	
    DM	12 (33)	8 (32)	
Sex, n (%)			
     Men	10 (28)	11 (44)	
     Women	26 (72)	14 (56)	
Age, years	60 (48-69)	57 (33-68)	
Disease duration, years	2.2 (0.1-6.7)	n/a	
ANA positivity, n (%)	18 (50)	n/a	











Physician’s global disease activity assessment, mm	13 (3-40)		







Extramuscularglobal assessment, mm	12 (0-29)		
ILD, n (%)	9 (24)		
Immunomodulatory drugs, n (%)	18 (50)	21 (84)	
Daily dose of Prednisolone, mg	4 (0-10)	8 (5-50)	
*All data are from time of blood sampling and presented as median (IQR; interquartile range) if not stated otherwise.
PM, Polymyositis; DM, dermatomyositis; MCTD, Mixed Connective Tissue Disorder; Disease duration, years from diagnosis till sampling date; ANA, antinuclear antibody analysed by ELISA. Physicians global disease activity assessment (Visual Analogue Scale (VAS), from 0-100 mm), Patients global disease activity assessment (VAS from 0-100 mm); Extramuscular global assessment (VAS from 0-100 mm); MMT8, Manual muscle test (0-100 %); HAQ, Health Assessment Questionnaire (potential score 0.00-3.00); CPK, creatine phosphokinase (normal levels: 0.6-3.5 µkat/liter); AST, Aspartate aminotransferase (normal levels <0.61 µkat/liter); ALT, Alanine aminotransferase (normal levels <0.76 µkat/liter); LDH, lactate dehydrogenase (normal levels <3.5 µkat/liter); ILD, Interstitial Lung Disease; Immunomodulatory drugs includes cyclophosphamide, methotrexate, azathioprine, cyclosporin A, and intravenous immunoglobulin; (n/a), not assessed.
† Autoantibodies to Jo-1; PL7; EJ; Ku; Ro52; Mi-2; SRP; U1RNP; La; TIF1 gamma. A patient is considered autoantibody positive if positive response in either the line immunoassay system or the immunoprecipitation assay. One patient could have several autoantibody specificities.
°One of these patients also had MCTD.
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